

Completed CV Outcomes Trials in T2DM

Study	SAVOR ¹	EXAMINE ²	TECOS ³	CARMELINA ⁴	CAROLINA ⁵
DPP4-i	saxagliptin	alogliptin	sitagliptin	linagliptin	linagliptin
Comparator	placebo	placebo	placebo	placebo	glimepiride (SU)
N	16,492	5380	14,671	6979	6103
Results	NEUTRAL	NEUTRAL	NEUTRAL	NEUTRAL	NEUTRAL

Study	ELIXA ⁶	LEADER ⁷	SUSTAIN 6 ⁸	EXSCEL ⁹	REWIND ¹⁰	HARMONY ¹¹	PIONEER-6 ¹²	AMPLITUDE O ¹³
DPP4-i	lixisenatide	liraglutide	SQ semaglutide	exenatide LR	dulaglutide	albiglutide	Oral semaglutide	efpeglenatide
Comparator	placebo	placebo	placebo	placebo	placebo	placebo	Placebo	Placebo
N	6068	9340	3297	14,752	9901	9463	3183	4026
Results	NEUTRAL	+	+	NEUTRAL	NEUTRAL	NEUTRAL	NEUTRAL	NEUTRAL

Study	EMPA-REG ¹⁴	CANVAS ¹⁵	DECLARE ¹⁶	VERTIS CV ¹⁷	CREDENCE ¹⁸	SOLOIST ¹⁹
SGLT2-i	empagliflozin	canagliflozin	dapagliflozin	ertugliflozin	canagliflozin	sotagliflozin
Comparator	placebo	placebo	placebo	placebo	placebo	Placebo
N	7020	4330	17,160	8246	4401	1222
Results	+	+	+	+/-	+	+

1. NCT01107886 (SAVOR). 2. NCT00968708 (EXAMINE). 3. NCT00790205 (TECOS). 4. NCT01897532 (CARMELINA). 5. NCT01243424 (CAROLINA). 6. NCT01147250 (ELIXA). 7. NCT01179048 (LEADER). 8. NCT01720446 (SUSTAIN 6). 9. NCT01144338 (EXSCEL). 10. NCT01394952 (REWIND). 11. NCT02465515 (HARMONY). 12. NCT02692716 (PIONEER 6). 13. NCT03496298 (AMPLITUDE-O). 14. NCT01131676 (EMPA-REG). 15. NCT01032629 (CANVAS). 16. NCT01730534 (DECLARE). 17. NCT01986881 (VERTIS CV). 18. NCT02065791 (CREDENCE). 19. NCT03521934 (SOLOIST-WHF)